Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease (SD). Histon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Foss, Francine, Horwitz, Steven, Pro, Barbara, Prince, H. Miles, Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785666/
https://ncbi.nlm.nih.gov/pubmed/26965915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0243-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados